



an Open Access Journal by MDPI

Novel Insights into Diagnosis and Therapy of Advanced Renal Cell Carcinoma

Guest Editor:

Prof. Dr. Giuseppe Lucarelli

Andrology and Kidney
Transplantation Unit,
Department of Emergency and
Organ Transplantation—Urology,
University of Bari “Aldo Moro”,
70124 Bari, Italy

Deadline for manuscript
submissions:

31 March 2025

Message from the Guest Editor

Renal cell carcinoma (RCC) is the most common type of kidney cancer, and in recent years, there has been a growing interest in identifying tumor markers not only for diagnostic purposes but also to improve the predictive power of clinical and pathological parameters.

The treatment landscape for advanced or metastatic RCC is rapidly evolving, with risk stratification being a crucial step in developing a treatment plan. Cytoreductive nephrectomy (CN) and surgical metastasectomy are still considered fundamental treatments in selected cases after evaluation by a multidisciplinary team. However, recent studies have shown that CN may not always be necessary, especially with the availability of systemic therapies like immune checkpoint inhibitor-based combinations that have shown superior outcomes compared to monotherapy with tyrosine kinase inhibitors.

This Special Issue of *Biomedicines* is dedicated to studies exploring the application of different approaches to understand the alterations in biological systems occurring in the pathogenesis of advanced RCC, as well as minimally invasive treatment and translational research for the diagnosis and management of this tumor.



mdpi.com/si/211049

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)